Everything below concerns GW501516. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual description for typical solid reference material. |
| Solubility | Poorly soluble in water; soluble in DMSO | Solubility depends on solvent, purity, and form. |
| Storage | Cool, dry, protected from light | Long-term storage often uses low temperature and desiccant. |
| Common analytical method | LC-MS/MS | Used for detection and quantification in biological matrices. |
| Common synonyms | GW-501516; GW501516; endurobol | Naming varies among literature, vendors, and databases. |
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
28 February to 28 February 1971 The 11th Light Infantry Brigade launched Operation Iron Mountain to attack PAVN/VC bases and logistics routes in southeastern Quảng Ngãi Province. The operation resulted in 4,589 PAVN/VC killed and 137 captured while U.S. losses are 440 killed.
== Associated organizations == Clinical Chemistry and Laboratory Medicine is the official journal of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM). It is also the official journal of the Association of Clinical Biochemists in Ireland, the Belgian Society of Clinical Chemistry, the German United Society of Clinical Chemistry and Laboratory Medicine, the Greek Society of Clinical Chemistry-Clinical Biochemistry, the Italian Society of Clinical Biochemistry and Clinical Molecular Biology, the Slovenian Association for Clinical Chemistry, and the Spanish Society for Clinical Biochemistry and Molecular Pathology.
=== Peripherally restricted === Peripherally acting μ-opioid receptor antagonists are used mainly in the treatment of opioid-induced constipation. These are designed to specifically inhibit certain opioid receptors in the gastrointestinal tract and with limited ability to cross the blood–brain barrier. Therefore, they do not affect the analgesic effects of opioids within the central nervous system.
Sources: en.wikipedia.org
=== Evaluation of the Degree of Effectiveness of Biobeam Low Level Narrow Band Light on the Treatment of Skin Ulcers and Delayed Postoperative Wound Healing === The study conducted (in 1992) double blind clinical trial under regular hospital conditioned showed statistical significant results in the treatment with narrow band red light (660 nm) in comparison to placebo. It proved that low light narrow band has a significant role in the treatment of skin ulcers and delayed amputees and operative wounds.
A series of WHO yaws control efforts, which began shortly after the creation of the WHO in 1948, succeeded in eradicating the disease locally from many countries, but have not lasted long enough to eradicate it globally. The Global Control of Treponematoses (TCP) programme by the WHO and the UNICEF was launched in 1952 and continued until 1964. A 1953 questionnaire-based estimate was that there were 50–150 million yaws cases in 90 countries. The global prevalence of yaws and the other endemic treponematoses, bejel and pinta, was reduced by the Global Control of Treponematoses (TCP) programme between 1952 and 1964 from about 50 million cases to about 2.5 million (a 95% reduction). However, "premature integration of yaws and other endemic treponematoses activities into weak primary health-care systems, and the dismantling of the vertical eradication programmes after 1964, led to the failure to finish with the remaining 5% of cases" and also led to a resurgence of yaws in the 1970s, with the largest number of case found in the Western Africa region. Following the cessation of this program, resources, attention and commitment for yaws gradually disappeared, and yaws remained at a low prevalence in parts of Asia, Africa, and the Americas with sporadic outbreaks. With few cases, mainly affecting poor, remote communities with little access to treatment, yaws became poorly known, yaws knowledge and skills died out even among health professionals, and yaws eradication was not seen as a high priority.
=== United States === In 2008, Pulver Spirits began developing a line of alcohol powder products to be marketed in the United States. The marketing was reportedly intended to be in full compliance with alcohol regulations and targeted at adults of legal drinking age. In Spring 2014, the Arizona-based company Lipsmark LLC announced that it would start marketing powdered alcohol under the name "Palcohol", a portmanteau of powder + alcohol. This caused considerable controversy, after the product was approved by the TTB for sale. This approval was later attributed to a "labeling error", and the manufacturer surrendered the approvals. In March, 2015, the U.S. Alcohol and Tobacco Tax and Trade Bureau (TTB) approved four powdered alcohol products with the brand name "Palcohol" for sale in the U.S. Under the Twenty-first Amendment to the United States Constitution, state and territory governments also have substantial regulatory powers over "intoxicating liquors", especially regarding retail sales and sales to minors. Shortly after the TTB approval was announced, the U.S. Food and Drug Administration (FDA) responded to inaccurate reports implying that it had approved powdered alcohol as being safe. The FDA clarified that its role was to evaluate the nonalcoholic ingredients and that based on its evaluation of specific powdered alcohol products it had no legal basis to block their entry into the U.S. market. In 2014, Ohio state legislators introduced legislation that would ban Palcohol and all other powdered alcohol. The following year, Iowa state legislators followed suit.
Sources: en.wikipedia.org
=== Lindow Man === Much about the local Iron Age history of Wilmslow was uncovered with the discovery of Lindow Man, in Lindow Moss. Preserved in the peat bogs for 2,000 years, Lindow Man is one of the most important Iron Age finds in the country. Despite a campaign to keep Lindow Man in the area, he was transferred to the British Museum and is a central feature of the Iron Age exhibition. He returned to Manchester Museum in April 2008 for a year-long exhibition.
Following the success of Counter-Strike, Valve went on to release multiple installments in the series. The first subsequent game, Counter-Strike: Condition Zero, which used Counter-Strike's GoldSrc engine, was released in 2004. Counter-Strike: Source, a remake of the original Counter-Strike, was the first game in the series to use Valve's Source engine and was also released in 2004, eight months after the release of Condition Zero. The next game in the Counter-Strike series was Counter-Strike: Global Offensive, released for Windows, OS X, Linux, PlayStation 3, and Xbox 360 in 2012. Counter-Strike 2, an updated version of Global Offensive, was released in 2023. The game spawned multiple spin-offs for the Asian gaming market. The first, Counter-Strike Neo, was an arcade game developed by Namco and released in Japan in 2003. In 2008, Nexon Corporation released Counter-Strike Online, a free-to-play installment in the series monetized via microtransactions. Counter-Strike Online was followed by Counter-Strike Online 2 in 2013. In 2014, Nexon released Counter-Strike Nexon: Zombies worldwide via Steam.
While still under debate, it appears likely that incorporation of water hydrogen isotopes is the more dominant process for kerogen D- enrichment during catagenesis. In summary, D content of kerogen and coal is complicated and hard to resolve due to the complex chemistry. Nevertheless, studies have found the possible correlation between coal δD and paleo-latitude.
Sources: en.wikipedia.org
Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.
Most methods use liquid chromatography with tandem mass spectrometry. Urine is common in anti-doping testing, and blood or plasma may be used in research.
Typical guidance is cool, dry, dark storage, often at low temperature and with desiccant. Stability data are limited, so storage conditions should be verified for each batch or supplier.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.